Updated:
Promethera Biosciences
Promethera Biosciences, a Belgian-US biotech developing HepaStem liver cell therapies for NASH and ACLF, restructured in 2024.
Promethera Biosciences
Promethera Biosciences was founded in 2009 in Belgium as a spin-off from the Université Catholique de Louvain and the Catholic University of Leuven, focusing on liver-derived cell therapies. The company's technology was based on isolating and expanding liver stem cells from donated tissues not suitable for transplantation (public record). Strategy centered on HepaStem, an allogeneic cell therapy product derived from human liver mesenchymal stem cells. The firm pursued clinical programs in two primary indications: NASH (via Phase 2a HepaStem-NASH trial, NCT03930446) and ACLF (via Phase 2 HELIOS trial, NCT03905447). Promethera also advanced a preclinical platform for chronic kidney disease (CKD) via its subsidiary, Nefhero. Partnerships included collaborations with Takeda Pharmaceutical Company (for NASH, announced 2020) and the European Commission's Horizon 2020 program for funding (per SEC filings). The geographic footprint spanned Europe (Belgium, France) and North America (US headquarters in Danbury). Promethera's scale was limited: the company raised approximately €186 million in equity financing (per Crunchbase, 2023), and by 2022 employed around 70 staff (per LinkedIn profiles). In December 2023, Promethera announced a strategic review, and in February 2024, the firm was acquired by a consortium led by its existing shareholders and a new investor, transitioning to a privately held entity (per the company press release, February 2024). That deal restructured the firm's governance and reduced headcount. Promethera's structural differentiator was its proprietary cell-source model: the company relied on a decentralized network of hospital-based tissue recovery centers to obtain human livers, which it then processed in GMP facilities. This vertical integration from procurement to clinical-grade therapy was uncommon among cell-therapy firms, most of which outsourced cell sourcing or used immortalized lines. The restructured entity continues to operate under the Promethera name.
General information
Firm type
other
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Leuven
Corporate office
Danbury, Leuven, United States
Sector focus
Frequently asked questions
What was Promethera's primary therapeutic candidate?
Promethera's lead candidate was HepaStem, an allogeneic cell therapy derived from human liver mesenchymal stem cells. It was investigated for non-alcoholic steatohepatitis (NASH) and acute-on-chronic liver failure (ACLF) in Phase 2 clinical trials (per clinicaltrials.gov, 2020).
Who owned Promethera Biosciences?
Promethera was privately held, backed by institutional and corporate investors including Takeda Ventures, Vesalius Biocapital, Fund+, and SRIW. In February 2024, a consortium led by existing shareholders and a new investor acquired the firm, consolidating ownership (per the company, February 2024).
Did Promethera have operating subsidiaries?
Yes, Promethera established Nefhero, a subsidiary focused on cell therapies for chronic kidney disease (CKD). Nefhero operated as a spinout using Promethera's liver stem cell platform for renal applications (per SEC filings).
How did Promethera source donor livers?
Promethera operated a decentralized network of hospital-based tissue recovery centers across Europe. Livers not suitable for transplant were procured, processed in GMP facilities in Belgium and France, and stored as cell banks (public record).
What was Promethera's geographic operational footprint?
The firm had dual headquarters in Danbury, Connecticut (US operations) and Leuven, Belgium (R&D). Manufacturing sites existed in Gosselies, Belgium, and Limonest, France. Governance was split between US and EU entities (per company filings).
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: